Promising data shows an Alzheimer's drug can slow cognitive decline, the Yahoo News website reports today (Dec. 1, 2022).
In a phase III clinical trial, with results published Nov. 29 in the New England Journal of Medicine, the drug, Lecanemab -- developed by Eisai and Biogen Inc. -- slowed the rate of cognitive decline by 27% in patients in the early stages of the disease, making it the first drug of its kind to produce such positive trial results.
It is also the first drug of its kind to be FDA approved.
No comments:
Post a Comment